HomeCompareAZNCF vs EPRT

AZNCF vs EPRT: Dividend Comparison 2026

AZNCF yields 1.65% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $40.4K in total portfolio value
10 years
AZNCF
AZNCF
● Live price
1.65%
Share price
$189.90
Annual div
$3.14
5Y div CAGR
10.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.9K
Annual income
$533.91
Full AZNCF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — AZNCF vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAZNCFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AZNCF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AZNCF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AZNCF
Annual income on $10K today (after 15% tax)
$140.55/yr
After 10yr DRIP, annual income (after tax)
$453.82/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $10,741.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AZNCF + EPRT for your $10,000?

AZNCF: 50%EPRT: 50%
100% EPRT50/50100% AZNCF
Portfolio after 10yr
$44.1K
Annual income
$6,852.38/yr
Blended yield
15.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

AZNCF
Analyst Ratings
1
Strong
16
Buy
15
Hold
4
Sell
Consensus: Buy
Altman Z
3.7
Piotroski
7/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AZNCF buys
0
EPRT buys
0
No recent congressional trades found for AZNCF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAZNCFEPRT
Forward yield1.65%3.97%
Annual dividend / share$3.14$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR10.5%29%
Portfolio after 10y$23.9K$64.3K
Annual income after 10y$533.91$13,170.85
Total dividends collected$3.3K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: AZNCF vs EPRT ($10,000, DRIP)

YearAZNCF PortfolioAZNCF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,883$182.71$11,212$512.01$329.00EPRT
2$11,850$205.34$12,689$692.09$839.00EPRT
3$12,910$230.91$14,521$944.30$1.6KEPRT
4$14,074$259.80$16,841$1,302.88$2.8KEPRT
5$15,351$292.48$19,841$1,821.64$4.5KEPRT
6$16,755$329.46$23,818$2,587.47$7.1KEPRT
7$18,300$371.36$29,230$3,744.65$10.9KEPRT
8$20,000$418.85$36,816$5,540.38$16.8KEPRT
9$21,872$472.73$47,806$8,413.17$25.9KEPRT
10$23,937$533.91$64,324$13,170.85$40.4KEPRT

AZNCF vs EPRT: Complete Analysis 2026

AZNCFStock

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Full AZNCF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this AZNCF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AZNCF vs SCHDAZNCF vs JEPIAZNCF vs OAZNCF vs KOAZNCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.